Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

Hangzhou Biotest Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,628	1,591	1,907	1,940	1,368	261.17
Short-Term Investments	-	-	10	-	-	-
Trading Asset Securities	-	60.26	-	100.06	360.84	-
Cash & Short-Term Investments	1,628	1,651	1,917	2,040	1,729	261.17
Cash Growth	-7.83%	-13.88%	-6.01%	18.02%	561.86%	1791.45%
Accounts Receivable	67.09	97.46	61.89	38.82	146.91	96.26
Other Receivables	1.54	4.27	2.8	1.6	8.32	10.34
Receivables	68.64	101.73	64.68	40.42	155.23	106.6
Inventory	75.12	73.4	99.32	135.2	141.7	92.39
Other Current Assets	49.21	51.57	5.37	19.6	7.2	7.82
Total Current Assets	1,821	1,878	2,087	2,235	2,033	467.99
Property, Plant & Equipment	412.89	408.81	261.58	244.68	231.02	138.65
Long-Term Investments	8.61	19.3	2.84	40	40	-
Other Intangible Assets	273.96	275.16	208.71	213.71	20.35	20.75
Long-Term Deferred Tax Assets	11.42	11.8	14.44	13.16	3.01	1.52
Long-Term Deferred Charges	-	-	0.11	0.21	0.29	4.86
Other Long-Term Assets	16.33	9.15	5.08	4.54	104.13	0.15
Total Assets	2,544	2,602	2,580	2,752	2,432	633.92
Accounts Payable	42.61	56.45	58.35	88.72	224.32	110.89
Accrued Expenses	7.73	19.08	20.02	25.94	26.32	21.33
Short-Term Debt	1.07	0.44	0.59	0.35	5.64	11.09
Current Portion of Leases	-	-	2.45	5.1	2.28	-
Current Income Taxes Payable	2.77	0.02	-	-	39	17.34
Current Unearned Revenue	12.95	7.39	47.16	44.68	18.56	8.93
Other Current Liabilities	41.63	95.23	20.85	6.28	1.44	20.99
Total Current Liabilities	108.76	178.62	149.43	171.08	317.56	190.58
Long-Term Leases	-	-	-	2.19	4.55	-
Long-Term Unearned Revenue	10.75	11.17	8.69	6.43	1.25	0.31
Long-Term Deferred Tax Liabilities	-	-	0.71	1.16	-	-
Other Long-Term Liabilities	-	-	-	8.43	-	-
Total Liabilities	119.51	189.79	158.82	189.29	323.36	190.89
Common Stock	106.67	106.67	106.67	106.67	106.67	80
Additional Paid-In Capital	794.6	790.45	813.33	814.94	814.94	12.24
Retained Earnings	1,552	1,543	1,510	1,638	1,185	351.2
Treasury Stock	-31.61	-31.61	-14.76	-	-	-
Comprehensive Income & Other	1.02	0.94	-0.36	1.21	0.7	0.7
Total Common Equity	2,422	2,409	2,415	2,561	2,107	444.14
Minority Interest	1.79	2.87	5.51	1.04	1.05	-1.11
Shareholders' Equity	2,424	2,412	2,421	2,562	2,108	443.02
Total Liabilities & Equity	2,544	2,602	2,580	2,752	2,432	633.92
Total Debt	1.07	0.44	3.04	7.64	12.47	11.09
Net Cash (Debt)	1,626	1,651	1,914	2,032	1,716	250.08
Net Cash Growth	-7.78%	-13.77%	-5.81%	18.43%	586.22%	-
Net Cash Per Share	15.27	15.68	17.96	19.05	19.80	3.13
Filing Date Shares Outstanding	109.16	106.29	104.56	106.67	106.67	80
Total Common Shares Outstanding	109.16	106.29	106.22	106.67	106.67	80
Working Capital	1,712	1,699	1,937	2,064	1,715	277.4
Book Value Per Share	22.19	22.67	22.74	24.01	19.75	5.55
Tangible Book Value	2,148	2,134	2,207	2,348	2,087	423.39
Tangible Book Value Per Share	19.68	20.08	20.77	22.01	19.56	5.29
Buildings	-	306.67	193.65	194.71	189.13	37.09
Machinery	-	96.17	90.92	81.61	66.19	37.92
Construction In Progress	-	87.23	39.65	9.85	-	88.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.